
- Volume 0 0
FDA Reviews Trexima for Treatment of Migraines
GlaxoSmithKline and POZEN Inc announced that the drugTrexima will be reviewed by the FDA for the acute treatmentof migraine headaches. The companies have proposed Treximaas the brand name for their combination of sumatriptansuccinate (Imitrex) and naproxen sodium (Aleve, for example)in a single-tablet form. Pending approval by the FDA, Treximacould be available to the public by the second half of 2006.
Ms. Farley is a freelance medical writer based in Wakefield, RI.
Articles in this issue
almost 20 years ago
CAN YOU READ THESE Rxs?almost 20 years ago
Bar Coding Thwarts Illegitimate Drug Usealmost 20 years ago
COMPREHENSIVE CARE CLINIC: DIABETES: Diabetes-related Stress and Depressionalmost 20 years ago
Hypertension Counseling Requires a Multifactorial Approachalmost 20 years ago
COMPOUNDING HOTLINEalmost 20 years ago
Pharmacy Law: Duty to Warn Waived When Patient Refuses Counselingalmost 20 years ago
EnterpriseRx Pharmacy Management Systemalmost 20 years ago
Hospital Installs Automated Medication Cabinetsalmost 20 years ago
"Smartphones" Help with Clinical Trial Informationalmost 20 years ago
HIT Needs Medicare's LeadershipNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.